Mirabaud & Cie’s Moderna MRNA Stock Holding History

Mirabaud & Cie’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.2M	Sell	17,154 -1,212	-7%	-$62.7K	0.48%	29
2026 Q1	$933K	Sell	18,366 -32,060	-64%	-$1.5M	0.38%	32
2025 Q4	$1.49M	Sell	50,426 -120	-0.2%	-$3.26K	0.48%	27
2025 Q3	$1.31M	Sell	50,546 -9,486	-16%	-$265K	0.41%	36
2025 Q2	$1.66M	Sell	60,032 -1,510	-2%	-$39.8K	0.53%	36
2025 Q1	$1.74M	Buy	61,542 +3,520	+6%	+$125K	0.6%	31
2024 Q4	$2.41M	Buy	58,022 +1,694	+3%	+$81K	0.77%	27
2024 Q3	$3.76M	Buy	56,328 +350	+0.6%	+$32.1K	1.09%	22
2024 Q2	$6.65M	Sell	55,978 -295	-0.5%	-$37.3K	2.25%	13
2024 Q1	$6M	Sell	56,273 -10,410	-16%	-$1.05M	2.11%	16
2023 Q4	$6.63M	Buy	+66,683	New	+$5.61M	2.21%	18

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Mirabaud & Cie's MRNA Position: Q2 2026 in Review

Mirabaud & Cie reduced its Moderna (MRNA) stake by 6.6% in Q2 2026, selling an estimated $62.7K and leaving 17,154 shares worth $1.2M. The position accounts for 0.48% of the portfolio, ranked #29.

Mirabaud & Cie first reported a position in MRNA in Q4 2023 and has held it in 11 quarters since. The position peaked at $6.65M in Q2 2024. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Mirabaud & Cie held 17,154 shares of Moderna worth $1.2M as of Q2 2026.
Mirabaud & Cie sold 1,212 Moderna shares in Q2 2026, an estimated $62.7K.
Moderna made up 0.48% of Mirabaud & Cie's portfolio in Q2 2026, its #29 holding.
Mirabaud & Cie first reported a position in Moderna in Q4 2023 and has held it in 11 quarters since.
Mirabaud & Cie's Moderna position peaked at $6.65M in Q2 2024.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Mirabaud & Cie's 13F filing for Q2 2026, filed 8 Jul 2026.